Article
Oncology
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, Luca Bertamini, Angelo Belotti, Monica Galli, Massimo Offidani, Elena Zamagni, Antonio Ledda, Mariella Grasso, Stelvio Ballanti, Antonio Spadano, Michele Cea, Francesca Patriarca, Mattia D'Agostino, Andrea Capra, Nicola Giuliani, Paolo de Fabritiis, Sara Aquino, Angelo Palmas, Barbara Gamberi, Renato Zambello, Maria Teresa Petrucci, Paolo Corradini, Michele Cavo, Mario Boccadoro
Summary: This study aimed to evaluate the efficacy and safety of different carfilzomib-based treatment approaches and maintenance therapy, showing that KRd plus ASCT demonstrated superiority in improving responses compared with other treatments, and carfilzomib plus lenalidomide as maintenance therapy improved progression-free survival compared with lenalidomide alone.
Article
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Summary: In patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, daratumumab plus lenalidomide and dexamethasone significantly improved overall survival and progression-free survival with no new safety concerns.
Article
Medicine, General & Internal
Graham H. Jackson, Charlotte Pawlyn, David A. Cairns, Ruth M. de Tute, Anna Hockaday, Corinne Collett, John R. Jones, Bhuvan Kishore, Mamta Garg, Cathy D. Williams, Kamaraj Karunanithi, Jindriska Lindsay, Alberto Rocci, John A. Snowden, Matthew W. Jenner, Gordon Cook, Nigel H. Russell, Mark T. Drayson, Walter M. Gregory, Martin F. Kaiser, Roger G. Owen, Faith E. Davies, Gareth J. Morgan
Summary: The study evaluated the efficacy and safety of using Carfilzomib in combination with other drugs to treat newly diagnosed multiple myeloma patients. Patients receiving Carfilzomib combination therapy were more likely to achieve better partial response and had significantly longer progression-free survival compared to the control group.
Article
Medicine, General & Internal
Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W. C. J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosinol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M. J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodriguez-Otero, Joan Blade, Philippe Moreau
Summary: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy showed significant improvement in progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tahamtan Ahmadi, Jon Ukropec, Tobias Kampfenkel, Jordan M. Schecter, Yanping Qiu, Himal Amin, Jessica Vermeulen, Robin Carson, Pieter Sonneveld
Summary: In this ongoing phase III trial, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death compared to pomalidomide and dexamethasone alone, demonstrating that it could be considered a new treatment option for relapsed or refractory multiple myeloma patients.
Article
Oncology
Jacob P. Laubach, Sascha A. Tuchman, Jacalyn M. Rosenblatt, Constantine S. Mitsiades, Kathleen Colson, Kelly Masone, Diane Warren, Robert A. Redd, Dena Grayson, Paul G. Richardson
Summary: The phase 1b study demonstrated the potential of Pano-RVd treatment for relapsed and refractory multiple myeloma, showing promise in overcoming lenalidomide and/or bortezomib resistance.
BLOOD CANCER JOURNAL
(2021)
Article
Oncology
Joshua Richter, Peggy L. Lin, Viviana Garcia-Horton, Patricia Guyot, Erin Singh, Zheng-Yi Zhou, Mark Sievert, Riley Taiji
Summary: In this study, the efficacy and safety of Isa-Kd was compared with Dara-Rd for early relapse in patients with RRMM. Isa-Kd showed better PFS, OS, and fewer TEAEs compared to Dara-Rd. These results suggest that Isa-Kd could be an effective treatment option for early relapse in non-lenalidomide refractory patients.
Article
Hematology
Lu Sun, Juan Wang, Linlin Shao, Chenglu Yuan, Hongguo Zhao, Daqi Li, Zhencheng Wang, Panpan Han, Yafei Yu, Miao Xu, Hongyu Zhao, Jihua Qiu, Hai Zhou, Xinguang Liu, Yu Hou, Jun Peng, Ming Hou
Summary: The study compared the activity and safety of dexamethasone plus oseltamivir versus dexamethasone alone as initial treatment in adult patients with primary immune thrombocytopenia. The results showed that the dexamethasone plus oseltamivir group had significantly higher initial and 6-month response rates than the dexamethasone group, with good tolerability, suggesting it could be an effective choice for the management of newly diagnosed primary immune thrombocytopenia.
LANCET HAEMATOLOGY
(2021)
Article
Hematology
Fredrik H. Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Ludek Pour, Ivan Spicka, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gabor Mikala, Laura Rosinol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A. Bakker, Roman Hajek, Maria-Victoria Mateos, Paul G. Richardson, Pieter Sonneveld
Summary: In patients with relapsed or refractory multiple myeloma, melphalan flufenamide plus dexamethasone demonstrated superior progression-free survival compared to pomalidomide plus dexamethasone.
LANCET HAEMATOLOGY
(2022)
Article
Oncology
Laura Rosinol, Benjamin Hebraud, Albert Oriol, Anne-Laurene Colin, Rafael Rios Tamayo, Cyrille Hulin, Maria Jesus Blanchard, Denis Caillot, Anna Sureda, Miguel Teodoro Hernandez, Bertrand Arnulf, Maria-Victoria Mateos, Margaret Macro, Jesus San-Miguel, Karim Belhadj, Juan Jose Lahuerta, M. Brigid Garelik, Joan Blade, Philippe Moreau
Summary: An integrated analysis of four clinical trials showed that the VRD regimen had superior efficacy and lower incidence of adverse events compared to the VTD regimen in newly diagnosed multiple myeloma patients eligible for transplantation.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Adam Walter-Croneck, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B. Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study compared the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in patients with newly diagnosed multiple myeloma. The results showed that the combination therapy group had longer progression-free survival compared to the lenalidomide monotherapy group. Further research is needed to confirm these findings.
Article
Medicine, General & Internal
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Spicka, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, Marie-Laure Risse, Gaelle Asset, Sandrine Mace, Thomas Martin
Summary: The study showed that the addition of isatuximab to carfilzomib-dexamethasone significantly improves progression-free survival and depth of response in patients with relapsed multiple myeloma, representing a new standard of care for this patient population.
Article
Oncology
Eric P. Winer, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Eva Munoz-Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas Turner, Stefania Zambelli, Nadia Harbeck, Fabrice Andre, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortes
Summary: Pembrolizumab did not significantly improve overall survival in patients with previously treated metastatic triple-negative breast cancer versus chemotherapy, indicating potential for further research in specific patient subpopulations and combination therapy for this disease.
Article
Oncology
Sun Young Rha, Do-Youn Oh, Patricio Yanez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel Gonzalez Fernandez, Jin Li, Maeve A. Lowery, Timucin Cil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S. Wyrwicz
Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy for locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. The results showed that participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity.
Article
Oncology
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, the combination of daratumumab plus lenalidomide/dexamethasone improved progression-free survival compared to lenalidomide/dexamethasone alone. This benefit was observed regardless of patients' frailty status. Daratumumab showed improved response rates and minimal residual disease negativity across subgroups.
Letter
Oncology
Juan-Jose Garces, Jesus F. San-Miguel, Bruno Paiva
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Microbiology
Emilio Bouza, Miguel Martin, Jose Enrique Ales, Nuria Aragones, Begona Barragan, Rafael de la Camara, Jose Luis Del Pozo, Valentin Garcia-Gutierrez, Ramon Garcia-Sanz, Diego Gracia, Vicente Guillem, Victor Jimenez-Yuste, Mari Cruz Martin-Delgado, Joaquin Martinez, Rafael Lopez, Alvaro Rodriguez-Lescure, Julian Ruiz Galiana, Ana Maria Sureda, Francisco Tejerina-Picado, Antoni Trilla, Antonio Zapatero, Esteban Palomo, Jesus San-Miguel
Summary: The exact number of solid organ tumors diagnosed each year in Spain is unknown, making it difficult to determine if the pandemic has led to a decrease in cancer diagnoses. However, indirect data suggests that the pandemic has resulted in later-stage diagnoses for some non-hematological neoplasms. Although there is a lack of strong evidence, oncology patients who contract COVID-19 appear to have poorer outcomes. The immune response to infection in cancer patients is influenced by factors such as the type of neoplasia, treatment received, and timing of treatment.
REVISTA ESPANOLA DE QUIMIOTERAPIA
(2023)
Article
Hematology
Catia Simoes, Maria-Carmen Chillon, David Martinez-Cuadron, Maria-Jose Calasanz, Maria-Belen Vridiales, Iria Vazquez, Montserrat Hernandez-Ruano, Benat Ariceta, Paula Aguirre-Ruiz, Leire Burgos, Diego Alignani, Sarai Sarvide, Sara Villar, Ana Alfonso Pierola, Felipe Prosper, Rosa Ayala, Joaquin Martinez-Lopez, Juan Miguel Bergua Burgues, Susana Vives, Jose A. Perez-Simon, Maria Garcia-Fortes, Teresa Bernal del Castillo, Mercedes Colorado, Mayte Olave, Juan I. Rodriguez-Gutierrez, Jorge Labrador, Marcos Gonzalez, Jesus F. San-Miguel, Miguel angel Sanz, Pau Montesinos, Bruno Paiva
Summary: Clonal evolution in acute myeloid leukemia (AML) can be reconstructed using integrated multidimensional flow cytometry (MFC) immunophenotyping and fluorescence-activated cell sorting (FACS) with next-generation sequencing (NGS). Mutational analysis of dysplastic cells and leukemic blasts at the onset of AML identified stable, branching, and clonal evolution patterns. Techniques other than single-cell multiomics can be used to detect measurable residual disease (MRD) and genetic traits associated with treatment resistance in patients achieving complete response (CR). Whole-exome sequencing revealed different clonal involvement in dysplastic myeloerythropoiesis, leukemic transformation, and chemoresistance.
Article
Hematology
Oliver Van Oekelen, Karthik Nath, Tarek H. Mouhieddine, Tasmin Farzana, Adolfo Aleman, David T. Melnekoff, Yogita Ghodke-Puranik, Gunjan L. Shah, Alexander Lesokhin, Sergio Giralt, Santiago Thibaud, Adriana Rossi, Cesar Rodriguez, Larysa Sanchez, Joshua Richter, Shambavi Richard, Hearn J. Cho, Ajai Chari, Saad Z. Usmani, Sundar Jagannath, Urvi A. Shah, Sham Mailankody, Samir Parekh
Summary: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T) therapy has shown remarkable efficacy in relapsed/refractory multiple myeloma patients. However, most patients eventually relapse despite high initial response rates. This study analyzed the salvage treatments and outcomes of patients with disease recurrence after BCMA-directed CAR T therapy.
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
LEUKEMIA & LYMPHOMA
(2023)
Article
Multidisciplinary Sciences
Giuseppe Auteri, Mattia Biondo, Camilla Mazzoni, Marta Venturi, Andrea Davide Romagnoli, Simona Paglia, Michele Cavo, Nicola Vianelli, Francesca Palandri
Summary: Fostamatinib is a newly approved SYK-inhibitor drug for chronic immune thrombocytopenia. It has a response rate of 40% in patients and is well-tolerated. This case report presents the first instance of sustained response after discontinuation of fostamatinib therapy for a patient with refractory immune thrombocytopenia.
Letter
Hematology
Enrique M. M. Ocio, Sara Bringhen, Joaquin Martinez-Lopez, Jesus San-Miguel, Stefania Oliva, Paula Rodriguez-Otero, Nadia Le Roux, Yvonne Dong, Severine Doroumian, Sandrine Mace, Maria-Victoria Mateos
Letter
Hematology
Catia Simoes, Sara Villar, Benat Ariceta, Juan-Jose Garces, Leire Burgos, Diego Alignani, Sarai Sarvide, David Martinez-Cuadron, Juan-Miguel Bergua, Susana Vives, Lorenzo Algarra, Mar Tormo, Pilar Martinez, Josefina Serrano, Pilar Herrera, Fernando Ramos, Olga Salamero, Esperanza Lavilla, Cristina Gil, Jose-Luis Lopez-Lorenzo, Maria-Belen Vidriales, Carmen Chillon, Jorge Labrador, Jose-Francisco Falantes, Maria-Jose Sayas, Rosa Ayala, Joaquin Martinez-Lopez, Ana Alfonso Pierola, Maria-Jose Calasanz, Felipe Prosper, Jesus F. San-Miguel, Miguel A. Sanz, Bruno Paiva, Pau Montesinos
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Leire Burgos, Luis-Esteban Tamariz-Amador, Noemi Puig, Maria-Teresa Cedena, Camila Guerrero, Tomas Jelinek, Sarah Johnson, Paolo Milani, Lourdes J. Cordon, Jose Perez, Marta Lasa, Rosalinda Termini, Albert Oriol, Miguel-Teodoro Hernandez, Luis Palomera, Rafael Martinez-Martinez, Javier de la Rubia, Felipe de Arriba, Rafael Rios, Maria-Esther Gonzalez, Mercedes Gironella, Valentin Cabanas, Maria Casanova, Isabel Krsnik, Albert Perez-Montana, Veronica Gonzalez-Calle, Paula Rodriguez-Otero, Vladimir Maisnar, Roman Hajek, Fritz Van Rhee, Victor Jimenez-Zepeda, Giovanni Palladini, Giampaolo Merlini, Alberto Orfao, Javier de la Cruz, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosinol, Joan Blade, Maria-Victoria F. Mateos, Jesus San-Miguel, Bruno Paiva
Summary: An algorithm to identify patients with MGUS-like phenotype in multiple myeloma (MM) and light-chain (AL) amyloidosis was developed and its clinical significance was validated. The presence of MGUS-like phenotype in smoldering MM was associated with lower rates of disease progression, while in newly diagnosed active MM, it retained independent prognostic value in terms of progression-free survival (PFS) and overall survival (OS). The algorithm also predicted different survival outcomes in patients with AL amyloidosis.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosinol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Gabriella Chirumbolo, Michele Dicataldo, Martina Barone, Gianluca Storci, Serena De Matteis, Noemi Laprovitera, Barbara Sinigaglia, Francesco Barbato, Enrico Maffini, Michele Cavo, Francesca Bonifazi, Mario Arpinati
Summary: Chronic GVHD (cGVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (HSCT) with no consistent biomarkers to predict its occurrence. This study aimed to evaluate the potential of antigen-presenting cell subsets and serum chemokine concentrations as biomarkers for cGVHD.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Thomas G. Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach, Michele Cavo, Philippe Moreau, Meletios Dimopoulos, Kwee Yong, Christina Tekle, Meredith C. Foster, Yvonne Barnes, Marie-Laure Risse, Joseph Mikhael
Summary: The role, timing, and impact of transplantation on further therapy after relapse in multiple myeloma (MM) are still being debated in the era of highly active novel agents. The impact of prior transplantation on treatment benefit from monoclonal antibodies in patients with relapsed/refractory MM (RRMM) is largely unknown. This subgroup analysis examined efficacy and safety in patients from the Phase 3 IKEMA study with and without previous transplantation.
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Hematology
Bruno Paiva, Irene Manrique, Meletios A. Dimopoulos, Francesca Gay, Chang-Ki Min, Sonja Zweegman, Raphael Teipel, Maria -Victoria Mateos, Nicola Giuliani, Michele Cavo, Christine Rojas Hopkins, Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash, Ivan Spicka
Summary: Measurable residual disease (MRD) evaluation is helpful in determining treatment duration in multiple myeloma (MM). However, limited longitudinal data exists on MRD during maintenance. This study investigated the prognostic value of MRD dynamics and found that MRD status at randomization and MRD dynamics during maintenance impact progression-free survival (PFS) risk. These findings support the significance of MRD assessment during maintenance in MM.